Recent Company News

• 09:18 AM ET Jun 03, 2025
  

  Evaxion Biotech awarded grant from Gates Foundation to design new polio vaccine ($2.72, 0.00)

• 07:39 AM ET May 27, 2025
  

  Evaxion Biotech reports Q1 EPS ($0.01) vs FactSet ($0.71) [2 est, ($0.76)-(0.65)]; provides business update ($1.88, 0.00)

• 07:30 AM ET May 27, 2025
  

  Evaxion announces business update and first quarter 2025 financial results

• 08:00 AM ET May 23, 2025
  

  Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

• 08:04 AM ET May 22, 2025
  

  Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 ($1.73, 0.00)

• 08:03 AM ET Apr 28, 2025
  

  Evaxion Biotech announces EVX-01 data to be presented at AACR ($1.65, 0.00)

• 07:34 AM ET Apr 01, 2025
  

  Evaxion Biotech reports FY EPS ($0.20) vs year-ago ($0.81) ($1.85, 0.00)

• 04:32 PM ET Mar 25, 2025
  

  Evaxion Biotech to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting ($1.75, 0.00)

• 04:04 PM ET Mar 13, 2025
  

  Evaxion Biotech files $50M ordinary shares shelf - F-3 ($1.79, 0.00)

• 08:05 AM ET Feb 25, 2025
  

  Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package ($2.44, 0.00)